1: De Rosa R, Palmerini T, Piscione F. Response to Letter of Li et al.: How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing? Int J Cardiol. 2018 Nov 15;271:30. doi: 10.1016/j.ijcard.2018.06.048. PubMed PMID: 30223360.

2: Li J, Yan G. How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing? Int J Cardiol. 2018 Nov 15;271:28. doi: 10.1016/j.ijcard.2018.05.121. PubMed PMID: 30223357.

3: Lee D, Song Y, Han M, Park D, Suh DC. Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms. Neurointervention. 2018 Sep;13(2):124-127. doi: 10.5469/neuroint.2018.01088. Epub 2018 Aug 31. PubMed PMID: 30196683; PubMed Central PMCID: PMC6132032.

4: Kitazono T, Ikeda Y, Nishikawa M, Yoshiba S, Abe K, Ogawa A. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel. J Thromb Thrombolysis. 2018 Nov;46(4):488-495. doi: 10.1007/s11239-018-1714-2. PubMed PMID: 30074128; PubMed Central PMCID: PMC6182384.

5: Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM. Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome. J Manag Care Spec Pharm. 2018 Aug;24(8):800-812. doi: 10.18553/jmcp.2018.24.8.800. PubMed PMID: 30058986.

6: Brunner S, Rizas K, Hamm W, Mehr M, Lackermair K. Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy. Int J Sports Med. 2018 Jul;39(8):646-652. doi: 10.1055/a-0631-3302. Epub 2018 Jun 14. PubMed PMID: 29902806.

7: Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016. JAMA Intern Med. 2018 Jul 1;178(7):943-950. doi: 10.1001/jamainternmed.2018.0783. PubMed PMID: 29799992; PubMed Central PMCID: PMC6145718.

8: Lu N, Li L, Zheng X, Zhang S, Li Y, Yuan J, Wei Q, Xu Y, Meng F. Synthesis of a Novel Series of Amino Acid Prodrugs Based on Thienopyridine Scaffolds and Evaluation of Their Antiplatelet Activity. Molecules. 2018 Apr 28;23(5). pii: E1041. doi: 10.3390/molecules23051041. PubMed PMID: 29710801; PubMed Central PMCID: PMC6102589.

9: Katayama Y, Kubo T, Ino Y, Kameyama T, Matsuo Y, Kitabata H, Terada K, Emori H, Aoki H, Taruya A, Shimamura K, Ota S, Tanaka A, Hozumi T, Akasaka T. The relationship between timing of prasugrel pretreatment and in-stent thrombus immediately after percutaneous coronary intervention for acute coronary syndrome: an optical coherence tomography study. Heart Vessels. 2018 Oct;33(10):1159-1167. doi: 10.1007/s00380-018-1167-8. Epub 2018 Apr 24. PubMed PMID: 29691643.

10: Bath PM, May J, Heptinstall S. Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets. 2018 Jul;29(5):425-430. doi: 10.1080/09537104.2018.1445839. Epub 2018 Apr 18. Review. PubMed PMID: 29667460.

11: De Luca L, Pennacchi M, Musumeci G, D'Ascenzo F, Gallo P, Rigattieri S, Granatelli A, Berti S, Gulizia MM, De Servi S, Bolognese L; a nome dei Ricercatori EYESHOT e SCOPE. [Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries]. G Ital Cardiol (Rome). 2018 Feb;19(2):101-110. doi: 10.1714/2868.28941. Italian. PubMed PMID: 29531382.

12: Parthasarathy R, Gupta V, Gupta A. Safety of Prasugrel loading in ruptured blister like aneurysm treated with a Pipeline device. Br J Radiol. 2018 Jun;91(1086):20170476. doi: 10.1259/bjr.20170476. Epub 2018 Mar 22. PubMed PMID: 29509490; PubMed Central PMCID: PMC6223270.

13: Chandrasekhar J, Baber U, Sartori S, Aquino M, Kini AS, Rao S, Weintraub W, Henry TD, Farhan S, Vogel B, Sorrentino S, Ge Z, Kapadia S, Muhlestein JB, Weiss S, Strauss C, Toma C, DeFranco A, Effron MB, Keller S, Baker BA, Pocock S, Dangas G, Mehran R. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can J Cardiol. 2018 Mar;34(3):319-329. doi: 10.1016/j.cjca.2017.12.023. Epub 2017 Dec 27. PubMed PMID: 29475531.

14: Nagao T, Toyoda K, Kitagawa K, Kitazono T, Yamagami H, Uchiyama S, Tanahashi N, Matsumoto M, Minematsu K, Nagata I, Nishikawa M, Nanto S, Abe K, Ikeda Y, Ogawa A. A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial. Expert Opin Pharmacother. 2018 Apr;19(6):529-535. doi: 10.1080/14656566.2018.1444029. Epub 2018 Mar 26. PubMed PMID: 29463150.

15: Ristorto J, Messas N, Marchandot B, Kibler M, Hess S, Meyer N, Schaeffer M, Tuzin N, Ohlmann P, Jesel L, Morel O. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors. J Atheroscler Thromb. 2018 Aug 1;25(8):674-689. doi: 10.5551/jat.40584. Epub 2018 Feb 8. PubMed PMID: 29415954; PubMed Central PMCID: PMC6099071.

16: Chatterjee A, Hillegass WB. The promise of effective P2Y(12) platelet receptor pretreatment: Not crushed yet. Catheter Cardiovasc Interv. 2018 Feb 1;91(2):251-252. doi: 10.1002/ccd.27512. PubMed PMID: 29405601.

17: Kucuk M, Celen MC, Yamasan BE, Kucukseymen S, Ozdemir S. Effects of prasugrel on membrane potential and contractile activity of rat ventricular myocytes. Pharmacol Rep. 2018 Feb;70(1):156-160. doi: 10.1016/j.pharep.2017.08.015. Epub 2017 Sep 1. PubMed PMID: 29367102.

18: Ottani F, Femia EA, Cattaneo M, Caravita L, Attanasio C, Galvani M. Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial. Int J Cardiol. 2018 Mar 15;255:8-14. doi: 10.1016/j.ijcard.2017.12.055. Epub 2017 Dec 27. PubMed PMID: 29336914.

19: Ozawa T, Suda M, Ikegami R, Takano T, Wakasugi T, Yanagawa T, Tanaka K, Ozaki K, Hirono S, Minamino T. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome. Int Heart J. 2018 Jan 27;59(1):21-26. doi: 10.1536/ihj.17-005. Epub 2017 Dec 27. PubMed PMID: 29279531.

20: Arbel Y, Bennell MC, Goodman SG, Wijeysundera HC. Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention. Can J Cardiol. 2018 Jan;34(1):31-37. doi: 10.1016/j.cjca.2017.10.004. Epub 2017 Oct 6. PubMed PMID: 29275879.